NASDAQ:SYN - Synthetic Biologics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.7996 +0.02 (+2.57 %) (As of 11/18/2018 02:46 AM ET)Previous Close$0.7996Today's Range$0.7601 - $0.799652-Week Range$0.75 - $25.48Volume139,151 shsAverage Volume312,226 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Synthetic Biologics, Inc., a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection, overgrowth of pathogenic organisms, and the emergence of antimicrobial resistance; and SYN-010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The company's preclinical products include an oral formulation of the enzyme intestinal alkaline phosphatase to treat local GI disorders and systemic diseases; monoclonal antibody therapies for the prevention and treatment of pertussis; and novel discovery stage biotherapeutics for the treatment of phenylketonuria. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland. Receive SYN News and Ratings via Email Sign-up to receive the latest news and ratings for SYN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SYN Previous Symbol CUSIPN/A Webwww.syntheticbiologics.com PhoneN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding Shares7,210,000Market Cap$0.00 OptionableNot Optionable Synthetic Biologics (NASDAQ:SYN) Frequently Asked Questions What is Synthetic Biologics' stock symbol? Synthetic Biologics trades on the NASDAQ under the ticker symbol "SYN." When is Synthetic Biologics' next earnings date? Synthetic Biologics is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for Synthetic Biologics. What is the consensus analysts' recommendation for Synthetic Biologics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synthetic Biologics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Synthetic Biologics. Has Synthetic Biologics been receiving favorable news coverage? Media coverage about SYN stock has been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Synthetic Biologics earned a coverage optimism score of 0.9 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the near future. Who are some of Synthetic Biologics' key competitors? Some companies that are related to Synthetic Biologics include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE). Who are Synthetic Biologics' key executives? Synthetic Biologics' management team includes the folowing people: Mr. Steven A. Shallcross, Interim CEO, CFO, Sec., Treasurer & Sec. (Age 57)Dr. Joseph A. Sliman, Chief Medical Officer (Age 45)Vincent I. Perrone, Director of Corp. CommunicationDr. Michael Kaleko M.D., Ph.D., Sr. VP of R&DDr. Raymond D. Stapleton Jr., Ph.D., Sr. VP of Manufacturing How do I buy shares of Synthetic Biologics? Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Synthetic Biologics' stock price today? One share of SYN stock can currently be purchased for approximately $0.7996. What is Synthetic Biologics' official website? The official website for Synthetic Biologics is http://www.syntheticbiologics.com. MarketBeat Community Rating for Synthetic Biologics (NASDAQ SYN)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 62 (Vote Outperform)Underperform Votes: 82 (Vote Underperform)Total Votes: 144MarketBeat's community ratings are surveys of what our community members think about Synthetic Biologics and other stocks. Vote "Outperform" if you believe SYN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/18/2018 by MarketBeat.com StaffFeatured Article: What is a Swap?